Yahoo Web Search

  1. Sort by

  1. Brainstorm's cell therapy succeeds in ALS mid-stage study

    Reuters via Yahoo! NewsJul 18 06:30 AM

    (Reuters) - Brainstorm Cell Therapeutics Inc said its experimental cell therapy was safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS), a progressive neurological disorder, in a mid-stage study. The New Jersey-based company's shares were up 7 percent at $3.21 in premarket trading on Monday. ALS, or Lou Gehrig's disease, is an invariably fatal neurological disorder that...

  2. Shares of Brainstorm Cell Therapeutics Inc. shot up 18% in premarket trade Monday, after the company said Phase II study of its treatment for Lou Gehrig's disease met its objectives.

  3. Drug developer Brainstorm Cell Therapeutics Inc said its experimental cell therapy was found safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS), a progressive neurological disorder, in a mid-stage study.

  4. Press Release

    PharmiWebJul 18 05:10 AM

    BrainStorm Cell Therapeutics Inc. Posted on: 18 Jul 16 HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 18, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced results from the recently completed U.S. randomized, double-blind, placebo-controlled phase 2 Study of NurOwn® in ...

  5. The results enable the company to continue clinical trials for its NurOwn treatment.

  6. HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 14, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...

  7. HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 14, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce results from the recently completed Phase 2 Study of...

  8. BrainStorm Cell Therapeutics Inc. (BCLI) will be announcing top line results from the U.S. phase II study of its investigational cell therapy NurOwn in patients with Amyotrophic Lateral Sclerosis today (July 18, 2016).

  9. HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 18, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced results from the recently completed U.S. randomized, double-blind, placebo-controlled phase 2 Study of NurOwn® in Patients with ALS. "I would like to thank the patients who ...

  10. BCLI: Phase 2 ALS Trial Shows Clinical Benefit From NurOwn™ Treatment

    Zacks Small Cap Research via Yahoo! FinanceJul 18 10:30 AM

    The data show that patients treated with NurOwn™ were more likely to see a decrease in the rate of decline as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) compared to those treated with placebo. ALS is a rapidly progressing neurodegenerative disease whereby the nerve cells in the brain and spinal cord that control muscle movement degenerate. Patients typically...

  1. 1234542 results